Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, Texas
Treatments:Biologic therapyHospital:The University of Texas M. D. Anderson Cancer Center
Drugs:Journal:Link
Date:Jul 2012

Description:

Patients:
This phase 2 study involved 38 mantle-cell lymphoma patients. The median patient age was 64 years and 92% were male.

Treatment:
Patients were treated with the biologic therapy agents lenalidomide and rituximab (a monoclonal antibody for CD20 that causes the immune system to attack tumor cells).

Toxicities:
The most severe toxicities were of grade 4 and included blood clots. Grade 3 fatigue and abdominal pain, as well as grade 2 infection, were reported.

Results:
The median overall survival was 24.3 months.

Support:
This study was supported by the pharmaceutical company Celegene.

Correspondence: Dr. Michael Wang; email: [email protected]



Back